Finance

Lists
DNLI:NASDAQ
Denali Therapeutics Inc
$19.86
+0.68%
(+0.14) 1D
Sep 21, 12:47:06 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DNLI...
Open
$19.99
High
$20.10
Low
$19.40
Mkt. cap
3.17B
Avg. vol.
1.32M
Volume
873.44K
52-wk high
$27.30
52-wk low
$12.58
EPS
-$2.84
Beta
1.01
Shares outstanding
159.85M
No. of employees
507
Open
$19.99
High
$20.10
Low
$19.40
Mkt. cap
3.17B
Avg. vol.
1.32M
Volume
873.44K
52-wk high
$27.30
52-wk low
$12.58
EPS
-$2.84
Beta
1.01
Shares outstanding
159.85M
No. of employees
507
About Denali Therapeutics Inc
CEO-
Employees507
Founded2013
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websitedenalitherapeutics.com
Analyst ratings
Based on 15 analysts giving stock ratings to DNLI in the past 3 months
Strong buy
Buy
15
Hold
0
Sell
0
12-month forecast
Based on 15 Wall Street analysts offering 12 month price targets for DNLI in the last 3 months.
Highest
Current $19.86
$42.00 (+111.53%)
Average
$35.92 (+80.91%)
Lowest
$26.00 (+30.95%)
Analyst
Recommendation
Action
Price target
Projected
Date
Mayank Mamtani
B. Riley Securities
Buy
Maintained
$35.00
+76.3%
08/25/2026
Jessica Fye
J.P. Morgan
Buy
Maintained
$29.00
+46.1%
08/11/2026
Andrew Fein
H.C. Wainwright
Buy
Maintained
$42.00
+111.5%
08/07/2026
Michael Yee
UBS
Buy
Reiterated
$34.00
+71.2%
08/07/2026
Sean Laaman
Morgan Stanley
Buy
Reiterated
$40.00
+101.5%
08/07/2026
Paul Matteis
Stifel Nicolaus
Buy
Reiterated
$41.00
+106.5%
08/07/2026
Charles Moore
Robert W. Baird
Buy
Maintained
$34.00
+71.2%
08/07/2026
Thomas Shrader
BTIG
Buy
Maintained
$39.00
+96.4%
08/06/2026
Tazeen Ahmad
Bank of America Securities
Buy
Reiterated
$31.00
+56.1%
08/07/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
08/06/2026
Myles Minter
William Blair
Buy
Maintained
-
-
08/07/2026
Unknown Analyst
Goldman Sachs
Buy
Maintained
$41.00
+106.5%
07/20/2026
David Hoang
Deutsche Bank
Buy
Reiterated
$35.00
+76.3%
07/16/2026
Unknown Analyst
Jefferies
Buy
Maintained
$40.00
+101.5%
07/13/2026
Laura Chico
Wedbush
Buy
Maintained
$26.00
+30.9%
07/13/2026
Jay Olson
Oppenheimer
Buy
Maintained
$40.00
+101.5%
05/11/2026
Rudy Li
Wolfe Research
Hold
Initiated
-
-
02/23/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.68 / -$0.54
-26.85%miss
Revenue / Est. (USD)
3.60M / 2.44M
+47.50%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
3.60M
Cost of goods sold
101.95M
97.90M
103.85M
97.11M
Cost of revenue
101.95M
97.90M
103.85M
97.11M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
35.48M
39.46M
33.51M
36.28M
Operating expense
35.48M
39.46M
33.51M
36.28M
Total operating expenses
137.43M
137.36M
137.36M
133.40M
Operating income
-137.43M
-137.36M
-137.36M
-129.79M
Other non operating income
-
-
-
-
EBT including unusual items
-126.90M
-128.45M
-128.45M
-127.55M
EBT excluding unusual items
-126.90M
-130.09M
-129.71M
-126.80M
Income tax expense
-
102.00K
-
-
Effective tax rate
-
-0.08%
-
-
Other operating expenses
-
-
-
-
Net income
-126.90M
-128.55M
-128.45M
-127.55M
Net profit margin
-
-
-
-3,539.21%
Earnings per share
-0.74
-0.73
-0.69
-0.68
Interest and investment income
10.73M
7.28M
7.83M
3.17M
Interest expense
-200.00K
-
-179.00K
-178.00K
Net interest expenses
10.53M
7.28M
7.65M
2.99M
Depreciation and amortization charges
-
-
-
-
EBITDA
-133.57M
-133.58M
-133.60M
-125.31M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps